Loading...
Market
Which company will receive full FDA approval for a therapy first in 2024?
2
Resolution / Starting Odds
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
FDA official announcements and website
Story
FDA Approves Afami-cel for Synovial Sarcoma, Advances Cosibelimab and Adagrasib-Cetuximab Therapies
Aug 12, 2024, 11:03 AM
The FDA has granted accelerated approval to afami-cel, an engineered T cell therapy, for the treatment of adults with synovial sarcoma. This marks a significant advancement in immunotherapy for solid tumors. Additionally, the FDA has accepted the Biologics License Application (BLA) for cosibelimab, a treatment for locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), following a resubmission to address previous deficiencies. Furthermore, the FDA has also granted accelerated approval to the combination of adagrasib and cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
FDA • 33%
EMA • 33%
Both • 34%
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
